Molnupiravir and risk of post-acute sequelae of covid-19: cohort study.

ABSTRACT:

Objective

To examine whether treatment with the antiviral agent molnupiravir during the first five days of SARS-CoV-2 infection is associated with reduced risk of post-acute adverse health outcomes.

Design

Cohort study.

Setting

US Department of Veterans Affairs.

Participants

229 286 participants who tested positive for SARS-CoV-2 between 5 January 2022 and 15 January 2023, had at least one risk factor for progression to severe covid-19, and survived the first 30 days after testing positive were enrolled. 11 472 participants received a prescription for molnupiravir within five days of the positive test result and 217 814 received no covid-19 antiviral or antibody treatment (no treatment group).

Main outcome measures

Risks of post-acute sequelae of SARS-Co

SUBMITTER: Xie Y 

PROVIDER: S-EPMC10126525 | biostudies-literature | 2023 Apr

REPOSITORIES: biostudies-literature